Synairgen Share Price | |
---|---|
Price | 6.60 |
Bid | 6.02 |
Ask | 7.18 |
Change | 0.15 (2.33%) |
Volume | 247,694 |
Open | 6.45 |
High | 0.00 |
Low | 0.00 |
Prev. Close | 6.45 |
Currency | GBX |
---|---|
Issue Country | GB |
Shares in Issue | 201.37m |
Market Capitalisation | £12.99m |
Market Size | 30,000 |
52 Week High | 14.00 |
52 Week High Date | 25-Apr-2023 |
52 Week Low | 4.20 |
52 Week Low Date | 22-Mar-2024 |
# Trades | 14 |
---|---|
Vol. Sold | 176,391 |
Sold Value | £10.53k |
Vol. Bought | 71,303 |
Bought Value | £4.77k |
PE Ratio | -0.736301 |
Earnings | -8.76 |
Dividend | 0.00 |
Yield | 0.00% |
Date | Time | Trade Prc | Volume | Buy/Sell | Bid | Ask | Value | |
---|---|---|---|---|---|---|---|---|
18-Apr-24 | 15:46:03 | 6.2984 | 7,748 | Sell* | 6.02 | 7.18 | 488.00 | O Ordinary |
18-Apr-24 | 15:41:00 | 6.2984 | 1,630 | Sell* | 6.02 | 7.18 | 102.66 | O Ordinary |
18-Apr-24 | 14:57:34 | 6.30 | 26,500 | Sell* | 6.02 | 7.18 | 1,670 | O Ordinary |
18-Apr-24 | 13:39:16 | 6.6928 | 70,000 | Buy* | 6.02 | 7.18 | 4,685 | O Ordinary |
18-Apr-24 | 13:08:42 | 6.2984 | 3,359 | Sell* | 6.02 | 7.18 | 211.56 | O Ordinary |
18-Apr-24 | 11:33:52 | 6.2984 | 26,000 | Sell* | 6.02 | 7.18 | 1,638 | O Ordinary |
18-Apr-24 | 11:08:28 | 6.2984 | 780 | Sell* | 6.02 | 7.18 | 49.13 | O Ordinary |
18-Apr-24 | 11:03:19 | 6.0548 | 205 | Sell* | 6.02 | 7.18 | 12.41 | O Ordinary |
18-Apr-24 | 11:02:24 | 6.716 | 156 | Buy* | 6.02 | 7.18 | 10.48 | O Ordinary |
18-Apr-24 | 11:01:53 | 6.716 | 147 | Buy* | 6.02 | 7.18 | 9.87 | O Ordinary |
Announced | Traded | Action | Notifier | Price | Currency | Amount | Holding |
---|---|---|---|---|---|---|---|
28-Jan-22 | 27-Jan-22 | Buy | Bruce Campbell held the position of Non-Executive Director at the time of this trade.Bruce Campbell | 189.42 | GBX | 621 | 8,520 |
28-Jan-22 | 27-Jan-22 | Buy | Bruce Campbell held the position of Non-Executive Director at the time of this trade.Bruce Campbell | 189.74 | GBX | 7,899 | 8,520 |
12-Aug-21 | 12-Aug-21 | Exercise of Option | John C Ward held the position of Finance Director at the time of this trade.John C Ward | 1.00 | GBX | 489,148 | 734,092 |
12-Aug-21 | 12-Aug-21 | Sell | Phillip David Monk held the position of Chief Scientific Officer at the time of this trade.Phillip David Monk | 140.00 | GBX | 220,878 | 423,934 |
12-Aug-21 | 12-Aug-21 | Exercise of Option | Phillip David Monk held the position of Chief Scientific Officer at the time of this trade.Phillip David Monk | 1.00 | GBX | 400,212 | 423,934 |
Synairgen is a drug discovery and development company founded to combat severe respiratory diseases. Discover SNG001, our breakthrough treatment for COVID-19.